Related Experiment Video

Updated: Aug 2, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 7, 2017

Diagnosis, risk factors, and treatment of vascular dementia

Oscar L Lopez1, Lewis H Kuller, James T Becker

  • 1Department of Neurology, 3501 Forbes Avenue, Suite 830, Pittsburgh, PA 15213, USA. lopezol@upmc.edu

Current Neurology and Neuroscience Reports
|August 25, 2004
PubMed

Insights

Diagnosing vascular dementia (VaD) remains challenging due to issues with dementia definition and vascular disease determination. Improved diagnostic criteria are crucial for understanding risk factors and conducting effective clinical trials for VaD.

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Modern neuroimaging and clinical evaluations aid cerebrovascular disease identification.
  • Clinical diagnosis of vascular dementia (VaD) presents significant challenges.
  • Neuropathologic studies reveal low sensitivity and high specificity in current VaD clinical criteria.

Purpose of the Study:

  • To highlight the diagnostic challenges in identifying vascular dementia (VaD).
  • To emphasize the need for improved diagnostic criteria for VaD.
  • To underscore the importance of refined VaD definitions for research and clinical trials.

Main Methods:

  • Review of current clinical criteria for VaD.
  • Analysis of neuropathologic findings related to VaD.
  • Discussion of diagnostic issues concerning dementia definition and vascular disease assessment.

Main Results:

  • Current VaD criteria exhibit low sensitivity and high specificity.
  • Cognitive deficits from cerebrovascular disease often co-occur with other pathologies like Alzheimer's disease.
  • Existing criteria for VaD are inconsistently defined, often mirroring Alzheimer's disease presentations.

Conclusions:

  • A more precise definition of VaD is essential.
  • Improved diagnostic standards are critical for understanding VaD risk factors.
  • Homogenous patient cohorts for drug trials necessitate better VaD diagnostic criteria.

More Related Videos

A Visual Approach for Inducing Dolichoectasia in Mice to Model Large Vessel-Mediated Cerebrovascular Dysfunction04:29

A Visual Approach for Inducing Dolichoectasia in Mice to Model Large Vessel-Mediated Cerebrovascular Dysfunction

Published on: May 17, 2024

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...